Arax Advisory Partners
TSHA icon

Arax Advisory Partners’s Taysha Gene Therapies TSHA Stock Holding History

Arax Advisory Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45K Buy
+360
New +$2.13K ﹤0.01% 4774
2026
Q1 		– Sell
-21
Closed -$116 – 4330
2025
Q4 		$116 Buy
+21
New +$102 ﹤0.01% 3803

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arax Advisory Partners's TSHA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 360 shares worth $2.45K. The stake represents ﹤0.01% of the portfolio and ranks #4774 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in TSHA as recently as Q4 2025.

Arax Advisory Partners first reported a position in TSHA in Q4 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Arax Advisory Partners held 360 shares of Taysha Gene Therapies worth $2.45K as of Q2 2026.
  • Taysha Gene Therapies was a new Arax Advisory Partners position in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4774 holding.
  • Arax Advisory Partners first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.